Fredericksburg, VANCT07700238Now EnrollingIRB Ready

Primary Immune Thrombocytopenia Clinical Trial in Fredericksburg, VA

Access cutting-edge primary immune thrombocytopenia treatment through this phase 3 clinical trial at a research site in Fredericksburg. Study-provided care at no cost to qualified participants.

Sponsored by Amgen

Quick Self-Assessment

See if you qualify for this Fredericksburg location

Preparing your pre-screening questions…

Expert Care in Fredericksburg

Access primary immune thrombocytopenia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related primary immune thrombocytopenia treatment provided free

Apply for This Fredericksburg Location

Check if you qualify for this primary immune thrombocytopenia clinical trial in Fredericksburg, VA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fredericksburg

    Convenient for VA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fredericksburg site if eligible
  4. 4Begin participation

About This Primary Immune Thrombocytopenia Study in Fredericksburg

This Phase 3 study is designed to evaluate the efficacy and safety of romiplostim in combination with predniso(lo)ne compared with predniso(lo)ne alone in adults with previously untreated Primary Immune Thrombocytopenia (ITP).

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

Age ≥18 years or adult legal age within country if older than 18 years.
Diagnosis of primary ITP according to the 2019 International Consensus (ICR) that is previously untreated and requires treatment.
Note: The investigator should ensure that the diagnosis of primary ITP is established by excluding other causes of isolated thrombocytopenia, as outlined in the 2019 ICR, which states that the diagnosis of primary ITP is principally based on the

Exclusion Criteria

of other causes of isolated thrombocytopenia.
Note: If emergency treatment is necessary, platelet count performed before emergency can be used for study inclusion.
Note: Emergency ITP treatment with any thrombopoietin receptor agonists (TPO-RAs), or splenectomy is not allowed.
Platelet count \< 30 × 10\^9/L or Platelet count \< 50× 10\^9/L with clinically significant bleeding before any medical intervention. Exclusion Criteria:
Life-threatening bleeding at randomization.
Known sensitivity or intolerance to any of the products to be administered during study (eg, uncontrolled diabetes) or to any Escherichia coli-derived product (eg, filgrastim, pegfilgrastim, certain insulins).
Uncontrolled hypertension before randomization.
Abnormal hepatic or renal function at screening.
History of total splenectomy.
Use of concurrent anticoagulation therapy and/or antiplatelet therapy.
Need for nonsteroidal anti-inflammatory drugs (NSAIDs) use and use of NSAIDs within 7 days before randomization.
Venous or arterial thrombotic event within 3 or 6 months, respectively, before randomization.
Other protocol-defined Inclusion/Exclusion may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fredericksburg?

Yes, this clinical trial (NCT07700238) has an active research site in Fredericksburg, VA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Primary Immune Thrombocytopenia Treatment Options in Fredericksburg, VA

If you're searching for primary immune thrombocytopenia treatment options in Fredericksburg, VA, this clinical trial (NCT07700238) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fredericksburg research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced primary immune thrombocytopenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all primary immune thrombocytopenia clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Fredericksburg, VA

See all multiple myeloma clinical trials recruiting in Fredericksburg — not just this study.

Browse Multiple Myeloma Trials in Fredericksburg →

Browse More Trials by Condition

Multiple Myeloma TrialsPulmonary Embolism TrialsThrombocytopenia TrialsIdiopathic Thrombocytopenic Purpura TrialsAll Conditions →

Ready to Join in Fredericksburg?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fredericksburg, VA